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Abstract
In Argentina, the HIV epidemic is characterized by the co-circulation of subtype B and BF recombinant viral variants. Nef is
an HIV protein highly variable among subtypes, making it a good tool to study the impact of HIV variability in the vaccine
design setting. We have previously reported a specific cellular response against NefBF with low cross-reactivity to NefB in
mice. The aim of this work was to analyze whether the co-administration of IL-12 and GM-CSF, using DNA and MVA vaccine
vectors, could improve the final cellular response induced. Mice received three DNA priming doses of a plasmid that express
NefBF plus DNAs expressing IL-12 and/or GM-CSF. Afterwards, all the groups were boosted with a MVAnefBF dose. The
highest increase in the magnitude of the NefBF response, compared to that induced in the control was found in the IL-12
group. Importantly, a response with higher breadth was detected in groups which received IL-12 or GM-CSF, evidenced as
an increased frequency of recognition of homologous (BF) and heterologous (B) Nef peptides, as well as a higher number of
other Nef peptide pools representing different viral subtypes. However, these improvements were lost when both DNA
cytokines were simultaneously administered, as the response was focused against the immunodominant peptide with a
detrimental response towards subdominant epitopes. The pattern of cytokines secreted and the specific-T-cell proliferative
capacity were improved in IL-12 and IL-12+GM-CSF groups. Importantly IL-12 generated a significant higher T-cell avidity
against a B heterologous peptide. This study indicates that the incorporation of DNA expressing IL-12 in DNA/MVA
schemes produced the best results in terms of improvements of T-cell-response key properties such as breadth, cross-
reactivity and quality (avidity and pattern of cytokines secreted). These relevant results contribute to the design of strategies
aimed to induce T-cell responses against HIV antigens with higher quality.
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Introduction
Thirty years has passed from the first reported cases of aids and,
despite the health community efforts, the epidemic has not been
stopped yet. The last report from the Joint United Nations
Program on HIV/aids (UNAIDS) estimated nearly 34 million
people [31.6 million–35.2 million] living with HIV at the end of
2010, while the new infections were estimated in 2.7 million [2.4
million–2.9 million] people [1]. HIV/aids is one of the major
health issues in developing countries, where it is difficult to access
to antiretroviral therapy. In these countries, only a few fraction of
the population in need of therapy has access to it. Undoubtedly the
most effective measure to combat the epidemic will be the
possibility to apply a safe and effective vaccine.
One of the challenges to solve in the HIV vaccine development,
is the high variability of the virus, which difficult the antigen
selection. The M group of HIV-1, responsible for the pandemic,
have been differentiated in ten subtypes (A–K) and sub-subtypes
(A1–A4 and F1–F2) [2]. Moreover, the complexity has been
elevated with the dissemination of 51 circulating recombinant
forms (CRF) with a defined genetic structure.
In Argentina, the number of HIV
+ people is estimated in
130.000 [3]. There are many studies on the HIV molecular
epidemiology in different Argentinean populations, where the
presence of B subtype and BF recombinant forms were described,
with a high prevalence of CRF12_BF variant [4,5,6]. These
recombinant forms were reported in other South American
countries such as Uruguay, Brazil and Ecuador, among others
[4,7,8,9]. Also, the relevance of subtype-specific immune responses
have not been totally defined [10,11,12], imposing the necessity of
considering the regional epidemic molecular patterns on the
vaccine designs.
Nef is an HIV protein used in different vaccine development
strategies [http://www.avac.org/ht/a/GetDocumentAction/i/
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e378013436] [13,14,15,16]. A feature that makes Nef a good vaccine
antigen candidate is its early expression in the viral life cycle [17],
making it a relevant target during the early steps of cell infection.
Furthermore, several reports show the early immunogenicity of
Nef [18,19,20]. Addo and coworkers studied HIV patients in
different infection stages and they observed that Nef and Gag were
the most recognized HIV proteins containining the highest density
of epitopes. They also demonstrated that the two most frequently
recognized peptides were from Nef [19]. On the other hand, Nef
and Env are the most variable HIV proteins, making them good
tools to study the impact of HIV variability on the immune cross-
recognition (amino acid difference between NefBF and NefB
24.5%).
During the last years, aids vaccine designs were focused on those
strategies able to generate a cellular immune response. This was
due to the evidences indicating that immune responses mediated
by cytotoxic T lymphocyte (CD8
+ T cells, CTL) played a central
role controlling HIV infection and progression to aids [21,22]. In
this sense, different findings from the basic area of vaccine research
suggest that three characteristics of the specific CD8
+ T-cells could
be involved in the control of the viremia: frequency, breadth of the
epitopes recognized and cell functional quality [23,24].
The Thailand phase III vaccine clinical trial consisted in four
doses of a canarypox viral vector (ALVAC-HIV) expressing Gag
and Pol (from subtype B, LAI) and Env (gp120 from CRF01_AE,
subtype E, linked to the transmembrane anchoring portion of
gp41, subtype B (LAI)), followed by two doses of a recombinant
bivalent Env protein AIDSVAX from subtypes E and subtype B
(MN). This was the first trial that demonstrated a modest
protection, exhibiting a vaccine effectiveness of 31.2%. However,
there were no differences in the viral load and CD4
+ T-cell counts
of people who became infected, whether they had received the
vaccine or placebo [25]. Importantly, in the Thailand trial, the
antigens used in the vaccine were matched to the prevalent
subtypes in the region where the vaccine was tested. The results
from the Thailand trial represented a breakthrough in the road
towards an HIV vaccine, suggesting that it will be important to
improve the vaccine-induced immune responses, for instance by
incorporating adjuvants during the immunization regimes or by
improving the vectors to be used. Even more, due to the high HIV
variability, it is critical to explore immunization strategies that
promote the generation of T cell responses with a broad reactivity,
being capable to recognize a wide spectrum of divergent viral
sequences.
Currently, one of the most commonly used strategies in the HIV
vaccine field is the prime/boost regimen, administering DNA
vectors at prime and viral vectors at boost [26]. For this strategy,
some of the most widely employed viral vectors belong to the
Poxviridae family, including vaccinia virus in its attenuated
variants MVA (modified vaccinia virus Ankara) [27], canarypox
(used in the test Thailand phase III [25]) and fowlpox based
vectors [28,29]. Given the limited immunogenicity of the DNA
vaccines, an area that has gained importance is the design of
‘‘rational’’ adjuvants is the used of cytokines or chemokines to
increase the immunogenicity of expressed antigens. Among these
molecules, the most studied include IL-12 (Interleukin-12) [30],
GM-CSF (colony-stimulating factor granulocyte-macrophage)
[31], IL-18 [32] and IL-15 [33]. It is considered that cytokines
would be good candidates to enhance immune responses due to
the central role they play in the modulation of the immune system,
controlling different aspects of the immune response [34]. For
instance, some cytokines have a dominant influence on the
polarization of CD4
+ T-cells toward different T-helper phenotypes
[34,35]. Dendritic cells (DCs) play a crucial role in adaptive
immunity by their ability to activate naı ¨ve T-cells and to direct the
differentiation and polarization of T-cells. By producing IL-12,
among other cytokines, mature DCs promote the differentiation of
CD4
+ T lymphocytes into IFN-c-producing Th1 cells, as well as
the differentiation of CD8
+ T lymphocytes into cytotoxic cells
[35]. Moreover, some studies suggest that IL-12 and IFN type I
could be considered as a signal 3 in the activation and
differentiation of CD8
+ T-cells. This signal could replace classical
adjuvants in vaccine formulation [36]. Another important
modulator cytokine is GM-CSF which acts on monocyte/
macrophages and all granulocytes. GM-CSF also controls DCs
and T-cell function, thus linking innate and adaptive immunity
[37]. Moreover, it is able to recruit professional antigen presenting
cells to the vaccine site administration and to enhance their ability
to take up foreign antigens [38]. It has been shown that IL-12 and
GM-CSF are able to increase the immune response against
hepatitis B virus, Leishmania and HIV antigens, among others
[31,32,39], and synergistic effects between these two adjuvants
were also described [40,41].
We have previously characterized NefBF immunogenicity after
its delivery from DNA and MVA vectors in a mouse model,
employing Nef as a tool to evaluate the impact of subtype B vs BF
variability in vaccine strategies. We found that NefBF delivered
from DNA and MVA vectors generated a response of high
specificity with low cross-reactivity against subtype B [42]. Taking
in account the high HIV variability, the aim of the present study
was to analyze if the co-administration of genetic adjuvants such as
IL-12 and/or GM-CSF, from DNA vectors, during the priming
immunizations in DNA/MVA schemes was able to modulate not
only the magnitude, but also the breadth and quality of the NefBF-
specific immune response generated, as well as the cross-reactivity
against other Nef subtypes.
Results
1. IL-12 and GM-CSF during the priming phase enhanced
the cellular immune response against NefBF
In a previous study, we evaluated the Nef-specific cellular
immune response generated after immunizing mice with DNA and
MVA vectors expressing Nef from the circulating recombinant
form CRF12_BF (NefBF) (three DNA doses as prime followed by
one MVA boost). Using this strategy, highly specific responses
were generated with low cross-reactivity against Nef from B
subtype (NefB) [42].
Due to the necessity and the relevance of generating cellular
immune responses with higher amplitude in the context of HIV-1
diversity, we decided to explore strategies able to enhance the
response generated after NefBF immunization and to investigate
the possibility of increasing cross-reactivity against other subtypes.
We hypothesized that the inclusion of cytokines such as IL-12 and
GM-CSF, which play a key role in the generation of a Th1-type
immune response [35,37,38] and were previously used to enhance
immune responses generated from DNA vectors [31,40,41], would
benefit the specific T cell responses generated in terms of not only
the magnitude, but also breadth and quality.
Immunization schemes consisted of three DNA priming doses,
spaced each other by 14 days, containing a NefBF expressing
DNA (DNAnefBF, 50 mg) plus IL-12 or/and GM-CSF expressing
plasmids (IL-12; GM-CSF, 50 mg of each one), separately or in
combination. Mice primed only with DNAnefBF (without cytokine
expressing DNAs) were used as the control group. Fourteen days
after the last DNA priming dose all the groups received a booster
dose of MVAnefBF (Figure 1A).
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response was evaluated in the spleen by quantifying the IFN-c
secreting cells by ELISPOT. In figure 1Bi (upper panel) the
magnitude of the immune response found in the different groups
against a pool of peptides representing the whole NefBF protein is
shown. The data shown correspond to median values obtained
from four to five independent experiments. The highest
magnitude of NefBF-specific immune responses was found in
those groups immunized with IL-12 alone in which a statistically
significant increment in magnitude was detected, when compared
to the control group (without adjuvants) (Mann Whitney test
p=0.031) (Figure 1Bi). IFN-c SFC/10
6 cells median for IL-12
group was 457 [range 275–622] versus 169 [range 79–296] in the
control group. In the groups receiving GM-CSF alone or in
combination with IL-12, we also detected an improvement in the
response generated, where IFN-c SFC/10
6 cells median for GM-
CSF and GM-CSF+IL-12 groups were 289 [range 142–477] and
296 [range 176–845], respectively. However, a higher variability
among the different independent experiments was found in these
groups, thus no statistically significant differences could be
detected (Fig. 1Bi).
Then, we calculated the n-fold increments in the magnitude of
the NefBF responses found in the cytokine-DNA groups as: the
responses found in the cytokine-DNA group/response detected in
the control group (Figure 1Bi). The highest increment was found
in the IL-12 groups (median 2.38 [range 2.71-1.21]), whereas
1.73- [range 1–1.91] and 1.53-fold [range 2.86-1.05] increments
were registered for the GM-CSF and GM-CSF+IL-12 groups,
respectively. Additionally, the NefBF-specific IL-2-secreting cells
were also evaluated in these groups by ELISPOT. We found an
enhanced response in the three groups with adjuvants, but the
highest response was found in IL-12+GM-CSF group (Figure S1,
Student’s t-test, p=0.003). When the cross-reactivity against NefB
was evaluated, responses 2- to 4-fold lower than the homologous
response were detected (Figure 1Bii). The highest responses
directed towards the heterologous NefB peptides were also found
in IL-12 group (median 103 [range 34–191]) but without reaching
statistical significance when compared to the control group
(median 67 [range 49–120]) (Figure 1Bii).
Taking together, these results show that IL-12 and GM-CSF
resulted effective genetic adjuvants to enhance the specific immune
response generated against NefBF. However, out of the different
immunization schemes analyzed, the administration of DNA IL-
12 alone induced significantly higher magnitude increments
against the homologous NefBF response.
2. Groups which received IL-12 or GM-CSF induced
cellular immune responses with higher breadth
The results depicted in the previous section showed the
capacity of IL-12 and GM-CSF to increment the magnitude of
the homologous NefBF response. Undoubtedly, an immune
response directed against HIV with higher breadth, having the
ability to recognize multiple antigens/epitopes and/or different
variants of the peptides targeted, is a desired feature to be hold
by a vaccine formulation. Therefore, we considered important
to do a deeper evaluation of the ability of these adjuvants to
improve the breadth of the generated response by analyzing in
first place which regions of the NefBF protein were targeted,
and then the level of cross-reactivity against different HIV
subtypes.
We divided the NefBF peptide set in pools representing the
different protein domains and these pools were used as stimulus
in the IFN-c ELISPOT assay. The pools represented the N-
terminal domain (N-t, comprising from the first amino acid (aa) to
83), the N-terminal Core (Nt-C, 84 to 115), the Oligomerization
domain and Central Core (OCC, 116–159), the Loop of the
protein (L, 160–187) and the C-terminal domain (C-t, 188–205)
[43]. First, the recognition frequency of the different protein
domains was analyzed (Figure 2A). Interestingly, it was found that
the three groups receiving any of the genetic adjuvants
recognized a higher number of protein domains. Mice from the
control group (receiving NefBF alone during the priming)
recognized the N-t and the L domain in all experiments. The
responses with higher amplitude were detected in the groups
which received IL-12 or GM-CSF as cells from these mice
recognized the N-t and L domains plus the pool representing the
OCC domain (Figure 2Ai). However, when both cytokines were
co-administered, positive responses against the N-t and OCC
pools were detected with a minor frequency. In order to further
illustrate differences in breadth of the response induced among
groups, the proportion of the total response directed against each
of the targeted peptide-pools was analyzed (Figure 2Aii). The
highest breadth was detected in the IL-12 group in which the
magnitude of the response was distributed more evenly along the
three protein-regions targeted, whereas in the other two groups
(GM-CSF and IL-12+GM-CSF) the response was more focused
against the L domain, on detriment of the other recognized
domains.
Then, having observed that the cytokines incremented the
amplitude of the specific response induced against the antigen,
we proceeded with the analysis of the cross-reactivity against
other subtypes. For this, we performed an ELISPOT assays
using the Nef PTE (Potential T-cell Epitopes) peptide set,
obtained from NIH AIDS Reagent Program, in which a total of
1 2 7p e p t i d e sr e p r e s e n t i n gA ,B ,Ca n dn o n - A B CH I V - 1
subtypes are included. In this case, the peptide set was divided
in three pools, N-terminal pool (first aa to 83, N-t), Central pool
( a a8 4t o1 5 9 ,C e n t )a n dC - t e r m i n a lp o o l( a a 1 6 0t o2 0 5 ,C - t ) .A s
it was found for the homologous peptides, the administration of
IL-12 or GM-CSF generated a cellular response that cross-
recognized a higher number of peptide-pools (Figure 2Bi).
However, when both genetic adjuvants (IL-12 and GM-CSF)
were co-inoculated, this improvement was lost. When the
percentage of the response directed against each pool was
analyzed (Figure 2Bii), again the IL-12 group showed the
response with the higher breadth.
Data from this section demonstrate that the utilization of the
cytokines separately improved the breadth of the response
Figure 1. IL-12 and GM-CSF incremented the magnitude of the specific immune response. A) Immunization schedule: Groups of 4 Balb/c
mice received the different immunization regimes depicted. Immunization doses (both priming and boost doses) were spaced by 14 days. B) Nine
days after the MVAnefBF boost dose, cellular immune responses against a pool of peptides representing i- NefBF or ii- NefB were evaluated in the
spleen, by quantifying specific IFN-c secreting cells by ELISPOT; i- Magnitude of the NefBF (homologous) response; n-fold increase represents the
increments in the responses generated in relation to those found in the control group. ii- Magnitude of the cross-reactivity responses detected
against NefB. Data represent the median values found in 4 to 5 independent experiments. Background values found in negative control wells were
subtracted (5 to 50 spots/10
6 cells). Mann Whitney test was applied, comparing NefBF responses between groups (* p,0.05). For the box and whisker
plots, the horizontal line represents the median, the boxes represent the interquartile range and the whiskers represent the minimum and maximum
values.
doi:10.1371/journal.pone.0037801.g001
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results were evidenced by evaluating both the recognition
frequency of homologous and heterologous peptides as well as
the percentage of the total magnitude directed towards the
different protein regions targeted.
3. Mapping of the NefBF peptides targeted after
immunization and the cross-reactive NefB counterparts
Our next aim consisted in the identification of the individual
Nef peptides targeted. We employed a matrix-peptide strategy
where each peptide was represented in two different peptide pools,
allowing for the identification of the reactive peptide by the
Figure 2. The use of DNA-IL-12 or DNA-GM-CSF during the priming phase in DNA/MVA schemes enhanced the breadth of the
cellular response induced. i Recognition frequency represent the proportion of experiments in which a positive IFN-c ELISPOT response was
found for each protein domain. ii Bars show the percentage of the whole response (obtained from the sum of the responses directed against each of
the five peptide pools) which is directed towards the different Nef domains. Red and blue arrows denote increments and decreases compared to
control group respectively. A) NefBF peptides were mixed in five pools representing the structural domains of Nef protein: N-terminal domain (N-t, 1–
83 aa), N-terminal Core (Nt-C, 84–115), Oligomerization domain+Central Core (OCC, 116–159), the Loop of the protein (L, 160–187) and C-terminal (C-
t, 188–205). Data are from two or three independent experiments for DNAck or control groups, respectively. B) PTE peptides were mixed in three
pools, representing N-terminal (N-t, 1–83 aa), Central (C, 84–159) and C-terminal (C-t, 160–205) Nef domains. Data are from three or four independent
experiments for DNAck or control groups, respectively.
doi:10.1371/journal.pone.0037801.g002
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were constructed: one with Nef BF peptides (BF matrix; consisting
of 12 pools of 6 peptides each one) and the other one with NefB
peptides (B matrix; consisting of 14 pools of 7 B peptides each
one). These matrix-peptide pools were used as stimulus in IFN-c
ELISPOT assays and in splenocyte cultures to later evaluate the
specific IFN-c secreted in the supernatants after 72 h by ELISA.
Seven putative positive peptides using the BF matrix were
detected: BF2, BF3, BF9, BF26, BF27, BF32 and BF33; and
three using the B matrix: B41, B49 and B84 (data not shown).
Afterwards, ELISPOT assays using individual peptides were
performed to corroborate the putative targeted peptides, and only
six BF and two B peptides were confirmed: BF2, BF3, BF26, BF27,
BF32, BF33, B41 and B84. Positive responses for overlapped
consecutive peptides, as observed for BF2–BF3, BF26–BF27 and
BF32–BF33 peptides, were assumed to be representative of the
same epitope thus the peptides with the higher response were
selected to perform the next experiments: BF3, BF26 and BF33.
Figure 3A depicts the localization of the individual BF and B
peptides targeted within the different Nef protein domains, thus
identifying the immunogenic peptides responsible for the responses
showed in Figure 2. Figures 3B and 3C show the analysis of the
recognition frequency of each individual peptide in the whole set
of experiments and the percentage of the response (out of the total
magnitude) directed towards these peptides. We found that the
BF33 peptide, located on the loop of the protein (aa 179–193),
resulted highly immunodominant, being the most frequently
recognized (Figure 3B). Also, this peptide was the most immuno-
genic, inducing the highest magnitude in all groups (Figure 3C).
All groups also recognized the BF3 peptide, located on the N-
terminal domain (aa 11–26), but with lower frequency and
magnitude than the BF33 peptide, evidencing a lower immuno-
genicity for this region of the NefBF protein (Figure 3B and C).
The BF26 peptide, located on the central core (aa 140–155), was
also recognized by the four groups, but with the lowest frequency
and magnitude (Figure 3B and C), suggesting to have subdominant
feature in this mice model. Interestingly, IL-12 or GM-CSF
administration induced a higher frequency of recognition for the
BF26 subdominant peptide (Figure 3B). Both frequency and
magnitude of recognition of the BF peptides were similar for
groups in which IL-12 or GM-CSF was delivered. However, when
both genetic adjuvants were simultaneously applied a significant
reduction in the amplitude was observed as BF33 accounted more
than the 80% of the magnitude of BF the response (Figure 3C).
Regarding the cross-reactivity recognition pattern, the B84
peptide (aa 181–195), homologous to BF33, was recognized by all
the groups, while the B41 peptide (aa 9–23), homologous to BF3,
was not recognized by animals from the IL-12+GM-CSF group.
In line with the results observed for the homologous peptides, IL-
12 and GM-CSF (administered alone, not in combination)
improved the frequency of recognition of the heterologous B
peptides (Figure 3B).
After the analysis of the Nef immunogenicity pattern, it was
demonstrated that by delivering IL-12 or GM-CSF as genetic
adjuvants during the priming doses, it is possible to induce cellular
responses with an improved breadth in terms of higher frequency
of positive responses as well as a more balanced response where
the magnitude was more evenly distributed towards the different
targeted epitopes.
4. Peptide sequence analysis
After the identification of the individual targeted peptides, we
proceeded with the analysis and comparison of their sequences. In
figure 4A, it is described the complete aa NefBF sequence in
comparison with the NefB one. Sequences and localization of the
BF and B peptides and of the consecutive peptides that gave a
positive response are shown. The peptide responsible for the
positive responses found against the N-t peptide pool was BF3
which differ from its heterologous counterpart B41 in five aa. Two
of them were located at each end of the peptide, while the other
three were almost in the middle of the overlapping sequence
between BF2 and BF3, where the potential minimal epitope is
probably located, marked with a gray box in the figure 4. Thus,
these three aa changes located near the middle of the epitope
might probably reduce the recognition of B41 by the T-cells. In
the case of the peptides located within the central core of the
protein (BF26–BF27 and the heterologous counterparts B73–B74),
we found that peptide B73 does not include the whole overlapping
sequence between BF26 and BF27 (potential minimal epitope)
what might explain its abrogated recognition. In the case of B74,
the peptide covers the overlapping sequence but has two aa
changes: one located on the carboxi-terminal end and the other
near the middle of the peptide, what might explain the absence of
cross-recognition.
When we analyzed the BF33 peptide sequence and compared it
to the heterologous peptide B84, four aa changes were detected in
the B sequence. Three of them were located in the carboxi-end of
the peptide and the other change (K to E) was located in a more
central position of the potential epitope. None of these changes
seemed to avoid recognition given the cross-reactivity observed in
all experiments. However, it must be noted that the magnitude of
B84 responses were always significantly lower compared to the
homologous (BF33) response.
Then, we performed an analysis of epitope prediction based on
the probability of binding to the H-2d MHC class I and II alleles
of the peptides used in our T-cell assays by employing software
tools [44] (Figure 4B). The analysis for the immunodominant
BF33 peptide indicated a high probability of being presented by
H-2 Dd MHC class I, middle scores to bind H-2Kd and Ld, and
low score to bind the H-2Ad class II molecule.
On the other hand, the subdominant BF3 showed low affinity
binding scores to any MHC allele. Conversely, high score for the
Dd allele and middle scores for Kd, Ld, Ad and Ed alleles were
obtained for the BF26 peptide. However, we were unable to detect
a high response against this peptide.
Finally, the B84 binding prediction to MHC alleles gave a good
score to bind to MHC class I alleles. In spite of this, responses
against this peptide were low. Probably due the aa differences with
the BF33 counterpart peptide, present in the immunogen-
constructs.
A prediction of the potential epitopes present on the whole
NefBF sequence expressed from the DNA and MVA vectors was
also performed. The analysis showed high affinity scores to the H-
2 Dd and Ed alleles (class I and II respectively), for sequences
comprised from aa 181 to 195, the region in which the BF33
peptide (aa 179–193) is located. The analysis also indicated that a
sequence comprised between aa 7 to 25 have a high score of
binding to Kd (class I) and middle score of binding to Ed (class II),
in concordance with the middle immunogenicity that was found
for the BF3 peptide (aa 12–26). These predictive values coincide
with our results. However for other sequences that also showed
high affinity to the other H-2d alleles (68–77, 135–144 to class I;
31–45 to class II) positive T-cell responses could not be found.
Therefore, these analyses indicate that the recognition pattern
of the immunogenic peptides identified could be explained by the
coincidence or divergence of the aa composition of the peptides.
However, the comparison between the immunogenic predictions
either for the individual peptide sequences or for the complete
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with the results obtained from in vivo experiments. Although
reactivity of murine T cells does not directly translate to humans,
the underlying principles of the molecular interactions involved in
triggering T cell responses are the same in both species, thus it
must be expected that results obtained here would be potentially
extrapolated to a human scenario.
5. IL-12 and GM-CSF improved the quality of the cellular
response against NefBF
There are several studies exploring correlation between
different characteristics of the specific T-cell response and the
control of aids progression. Certain T-cell properties, such as their
polyfunctionality or their capacity to proliferate as well as the T-
cell avidity, have been directly correlated with enhanced anti-viral
immunity. In this sense, it has been described in different models
(such as SIV, cohorts of chronically HIV-infected patients,
controller patients and HIV-exposed seronegative persons) that
the polyfunctional CD8
+ T-cell responses, in terms of capacity to
secrete multiple cytokines, may play an important role in the
control of viral replication, with a direct correlation with
protection [45,46].
Thus, in order to address a deeper study of the immune
response generated with these immunization schemes, we studied
the cytokine secretion pattern induced against the different Nef
peptides targeted. To this aim, the secretion of IFN-c, TNF and
IL-2 in the supernatant of cell-cultures re-stimulated for 72 h with
the targeted peptides was evaluated by ELISA (Figure 5). The
Pattern of cytokines secreted against the immunodominant BF33
peptide showed that statistically significant increments -compared
to the control group- in the levels of IFN-c and TNF were detected
Figure 4. Sequence analysis and localization of B and BF peptides targeted. A) Comparison between amino acid sequences of NefBF and
NefB proteins, and BF and B peptides targeted. Grey boxes indicate the overlapping peptide sequences between the BF recognized peptides,
suggesting the potential epitope. B) Peptide immunogenicity of the response found is compared with the predicted MHC affinity. Prediction analysis
were made with the SYFPEITHI Epitope Prediction (Class I: Ld and Kd; Class II: Ad and Ed) and PREDEP (Class I: Dd) prediction softwares.
doi:10.1371/journal.pone.0037801.g004
Figure 3. NefBF and NefB peptides targeted. A) Nef Structural domains are represented and the localization of the targeted BF and B peptides
is indicated. B) Recognition frequency represents the proportion of experiments in which a positive response was found for each indicated peptide.
Red and blue arrows indicate differences (increments and reductions, respectively) compared to the control group. C) Bars show the magnitude
median of the responses (number of IFN-c secreting cells, evaluated by ELISPOT) detected in each group towards the different identified peptides.
Data are from two to four independent experiments for the different groups and peptides.
doi:10.1371/journal.pone.0037801.g003
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37801Figure 5. IFN-c, TNF and IL-2 secretion pattern after re-stimulation with homologous or heterologous peptides. Spleen cells from mice
immunized with 3xDNA/MVAnefBF plus IL-12 or/and GM-CSF (as depicted in Figure 1) were re-stimulated during 72 h with the indicated peptides.
Levels of IFN-c, TNF and IL-2 secreted in supernatants were quantified by ELISA. Bars represent the average levels of cytokines secreted in cell
supernatants from pooled samples of triplicate cultures. Negative controls (RPMIc) values were subtracted (,130 pg/ml for IFN-c, ,30 pg/ml for TNF
and ,14 pg/ml for IL-2). Cut-off levels (RPMI values+2xSD) are shown by horizontal grey lines. Significant differences between responses found in
control vs the other three groups are indicated with ** (p,0.01) and * (p,0.05).
doi:10.1371/journal.pone.0037801.g005
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were also incremented in the three groups, but significant
differences were only detected in the IL-12+GM-CSF group.
The improvement in the T-cell responses generated in relation to
the multiple cytokines secreted was more evident in the analysis of
the response against the subdominant BF26 peptide. Whereas in
the control group only a positive IL-2 response, slightly above the
cut-off value was detected, significant positive levels of the three
cytokines were found in both the IL-12 and IL-12+GM-CSF
groups. In relation to the cross-reactivity response detected, the
pattern of cytokines secreted against the B84 peptide was
significantly improved in both the IL-12 and IL-12+GM-CSF
groups in comparison to the control, detecting significant
increments in the levels of the three cytokines (see Figure 5).
Another quality of the T-cell responses that correlated with
effectiveness in their effector functions is the cellular avidity for the
antigen. In this line, a recent study demonstrated that HIV
controllers harbor a pool of memory CD4
+ T cells with the
intrinsic ability to recognize minimal amounts of Gag antigen,
which may explain how they maintain an active antiviral response
in the face of very low viremia [47].
Thus, our next aim was to explore the functional avidity of the
T-cells in our model. In these experiments, the responses found in
the control vs the IL-12 group were compared, analyzing the
avidity of the T-cells against the BF33 (same sequence as the
immunogen vectors) or the B84 peptide (with 3 aa changes, see
Figure 4), in order to define if the recognition pattern differed
between homologous or heterologous responses. T-cell avidity was
analyzed performing ELISPOT assays at different peptide
concentrations, making serial peptide dilutions (Figure 6A).
Intra-group analysis indicated that the sensitizing dose of
peptide concentration required to yield 50% of the maximal T-
cell IFN-c response (SD50) was significantly higher, indicating a
lower avidity, for the B84 compared to the BF33 in both the
control group (SD50: BF33 [0.0676 mg/ml] vs B84 [1.246 mg/ml];
p,0.0001) and in the IL-12 group (SD50: BF33 [0.0995 mg/ml] vs
B84 [0.4414 mg/ml]; p,0.0001). These results demonstrated that
a higher T-cell avidity for the homologous BF33 peptide
compared to the heterologous B84 peptide was found in both
groups analyzed.
An intergroup analysis revealed statistically significant differ-
ences in the T-cell avidity against the B84 peptide. Interestingly,
the highest avidity against this peptide was found in the group
receiving IL-12 as adjuvant. In this group the value of the SD50
was 3-fold lower compared to the control group (control group:
B84=1.246 mg/ml vs IL-12 group: B84=0.4414 mg/ml,
p=0.001). These results indicate that the administration of IL-
12 improved the cross-reactive response generating a T-cell
recognition of the heterologous B84 peptide with higher avidity
being able to recognize concentrations three-fold lower of the B
peptide ligand in comparison to the T cells from the control group.
Mean spot sizes, as a way to measure the IFN-c secretion
potency of the specific T-cells against BF33 or B84 (using the
ImmunoSpot software) were also analyzed. In correlation with the
higher avidity for the homologous BF33 peptide, the spot size was
higher when cells were re-stimulated with the homologous peptide:
B84 median spot size was 2.65-fold lower than BF33 spots [range
6.3-1.5], without differences between both immunized groups.
Finally, the proliferative capacity of the BF33 T-cell responses
induced after immunization was analyzed. In these assays,
cryopreserved splenocytes from control group, Il-12 and IL-
12+GM-CSF groups were used. It must be noted that in previous
experiments performed in our lab, a good correlation between T
cell assays performed with fresh and cryopreserved cells was
always registered [42].
Proliferation was evaluated on thawed and then rested cells by
the CFSE dilution assay. Briefly, after five days of stimulation in
the presence of the peptide or medium alone, viable CD4
+ and
CD8
+ T-cells that had proliferated were determined by flow
cytometry. As the epitope prediction analysis anticipated (Figure 4),
CD4
+ and CD8
+ proliferating BF33-specific cells were found
(Figure 6Bi and ii). Significant increments in the proportion of
proliferating CD4
+ and CD8
+ T-cells were observed in IL-12 and
IL-12+GM-CSF groups, compared to the control group
(Figure 6Bii). Only 0.355% of CD4
+ T-cells from the control
group proliferated, whereas values found for IL-12 and IL-
12+GM-CSF groups were 0.903 and 0.940% respectively,
rendering a 2-fold increment in the CD4
+ proliferating cells
(Figure 6Bi, left panel). When the CD8
+ T-cells were analyzed, no
proliferation was found in the groups without adjuvant. However,
1.395% and 1.855% of CD8
+ T-cells proliferated in IL-12 and IL-
12+GM-CSF groups, respectively (Figure 6Bi, right panel).
Altogether, data from these experiments showed that by
delivering of IL-12 or IL-12+GM-CSF from DNA vectors in
DNAprime-MVAboost regimes, the quality of the T-cell response
induced could be improved. This fact was confirmed by the
findings showing that a more complex array of cytokines was
produced against different peptides and both CD4
+ and CD8
+
specific T-cells showed superior proliferative capacities. Moreover,
we could demonstrate that, after IL-12 administration, T-cell
avidity against the heterologous B84 peptide was significantly
improved.
Discussion
More than a dozen antiretroviral drugs have been developed
since HIV/aids was first described, leading to a significant
decrease in mortality associated with aids over the years and
increasing the life quality of HIV infected people. These
improvements have occurred especially in developed countries,
where the therapy is available for all HIV
+ individuals, whereas
only during the last years ARV therapy have begun to be
implemented in developing countries [48]. Despite these advances,
HIV continues to spread around the world with an estimated rate
of 7400 new infections per day [1]. A critical obstacle in HIV
vaccine development is how to induce immune responses able to
overcome the intra- and inter-subtype viral variability. In
Argentina, the epidemic is characterized by the co-circulation of
subtype B variants and BF recombinant forms, mostly related to
the CRF12_BF [4,5]. One way to conquer the variability
challenge could be the design of multivalent vaccines, based on
formulations including antigens from the different HIV subtypes
that circulate in certain geographic areas. In fact, the RV144
clinical trial (performed in Thailand) included both antigens from
subtype B (widely distributed around the world, mainly in
developed countries) and CRF01_AE, prevalent in Thailand
[25]. Different preclinical studies also described the use of different
vectors expressing proteins from different clades [15,29,49].
During the last years, our laboratory have studied different
biological aspects (associated with the replication and immunoge-
nicity) of the CRF12_BF and its related variants, with particular
emphasis in viral regions which differed from the parental B
subtype [20,42,44,50,51]. In particular, we have recently reported
the construction of viral and DNA vectors expressing NefBF and
EnvBF. These vectors were administered by different immuniza-
tion schedules, in a mice model, inducing a specific BF response
with low B cross-reactivity [42,44]. It is not completely defined
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to fight against the HIV infection, but several studies point to a
high magnitude, breadth and polyfunctionality as desirable
features for a vaccine candidate [23,24]. To achieve these T cell
characteristics we considered the utilization of adjuvants to
generate an enhanced and improved response.
DNA plasmids expressing murine IL-12 and GM-CSF as
potential adjuvants to enhance the immune response generated by
DNA-prime/MVA-boost immunization schemes were used.
When the cytokine modulation effects on the magnitude of the
response against the total NefBF protein was analyzed, the higher
increments were found when IL-12 was administrated alone
(median of 2.38 fold vs the control group). On the other hand,
when GM- CSF was administered alone or combined with IL-12,
the observed increments were lower (medians of 1.535 and 1.73
fold increments compared to control). Surprisingly, in the groups
which received both genetic adjuvants we could not find a
synergism nor even an additive effect of the cytokines in relation to
the final magnitude detected.
Different previous reports accounted for the benefits of IL-12
administration in the context of HIV antigens [30,41]. For
instance, in a recent macaque study, the administration of DNA
expressing SIV antigens plus DNA expressing IL-12, boosted with
Ad5, generated a reduction of the median SIV peak and set point
viral loads [52]. However, IL-12 modulating effects on the
amplitude of the response generated after vaccination and its
impact on cross-reactivity frequency against different HIV
subtypes have not been studied previously. When we analyzed
the amplitude of the response generated, by evaluating the
frequency of recognition of the different NefBF protein domains,
differences among groups were detected. Interestingly, all the
groups gave a positive response against the N-t and L domains, but
the OCC domain was only recognized in those groups which
received any of the adjuvants, indicating that the highest breadth
was obtained in the groups which received any of the adjuvant-
treatments. To denote, mouse groups in which IL-12 or GM-CSF
were applied alone recognized the N-terminal, OCC and L
domains with the highest frequency, and the percentage of the
magnitude against these responses was more evenly distributed
(Figure 2A). Cross-reactivity against Nef of different subtypes was
evaluated with the use of PTE peptides (representing Nef
sequences of A, B, C and non-A,B,C subtypes). In this case, the
best results in terms of recognition frequency and magnitude
percentage distribution against the different peptide-pools, were
obtained in the IL-12 group.
Regarding the consequences that the use of different adjuvants
could have on the breadth of the T-cell responses induced, it has
been previously reported that IL-12, also administered from a
DNA vaccine in conjunction with DNA expressing SIV Gag,
increased the specific cellular response induced [53]. In concor-
dance with our results, the authors demonstrated a significant
correlation between the magnitude and breadth of the T-cell
response induced in the vaccines. Another recent study in which
soluble CD40 ligand was used as an adjuvant, also indicated an
improvement in both the magnitude and breadth of the T-cell
response generated by the use of the adjuvant in conjunction with
DNA expressing HIV antigens during the priming doses in DNA/
MVA or NYVAC immunizations [54].
When the response was split up into the single peptides targeted,
it was found that the majority of the response was directed towards
the BF33 peptide (aa position 179–193), located in the intersection
of the loop and the C-terminal domains of the protein. This
peptide was recognized both by CD4
+ and CD8
+ T-cells, as the
prediction analysis anticipated and as Santoro Rosa et al. described
previously [55]. Also, this peptide sequence had been previously
reported to be immunogenic in Balb/c mice in different reports
[13,55,56,57]. The cross-reactivity (against B84 peptide) was
improved by the employment of the adjuvants, but this response
always remained lower than the homologous response. The aa
changes in this protein portion, located at both ends of the peptide,
did not ablate but depressed the recognition by the T-cells. These
changes probably generated weaker interaction between the
peptide and MHC, thus failing in the activation of T lymphocytes.
The fine mapping of the rest of the NefBF T-cell epitopes
targeted, included subdominant peptides as the BF3 (aa position
12–26 aa) with some cross-reactivity with B41 (9–23 aa). These
peptides are located in the N-terminal portion of the protein.
There are five aa changes between them, three located in the
central part of the sequence, which probably prevented the
peptide recognition by the TCR or its interaction with MHC
molecules. To denote, this Nef region has not been described
previously to be immunogenic in Balb/c mice but for one earlier
study where, in coincidence with our results, the authors described
a low immunogenicity for it (,20% of responder mice) [13]. The
other BF peptide mapped was BF26 (aa position: 140–155), for
which we registered the lowest responses. Again, the only previous
report in which this region was cited to be immunogenic in Balb/c
mice was the study of Hinkula et.al., reporting for it a low
proportion of responsiveness (,20%) [13].
When we evaluated the IFN-c, TNF and IL-2 secretion pattern
for, data showed that, by co-delivering IL-12 or IL-12+GM-CSF
from DNA vectors in DNAprime-MVAboost regimes, the quality
of the T-cell response induced could be improved. As a result, a
more complex array of cytokines was produced against the
different peptides targeted and, importantly, both CD4
+ and
CD8
+ specific T-cells from these mice groups showed superior
proliferative capacities.
When T-cell functional avidity was analyzed, no differences
between IL-12 and control groups were found against the
immunodominant BF33 peptide. But interestingly, we demon-
strated that in the IL-12 group, a significant higher avidity was
found against the heterologous B84 peptide. Thus, we could
determine that mice from this group not only had an increment in
the frequency of positive responses against the B peptides
(Figure 3B) but also exhibited an enhanced T-cell avidity against
at least one (B84) of the cross-reactive B peptides. As mentioned
above, comparing the BF33 vs B84 peptide sequences four aa
substitutions were located at the ends of the B84 peptide allowing
Figure 6. IL-12 and GM-CSF improved the quality of the cellular immune response. A) Functional avidity of the BF33- and B84-specific T-
cells: Groups of 4 mice received the immunization schemes depicted in Figure 1 for the group 1 (NefBF alone) and group 2 (plus IL-12 during the
priming phase). Nine days after the MVA boost, T- cell avidity against BF33 and B84 peptides was evaluated using serial dilutions of the peptides.
Peptide concentrations used ranged from 20 to 0.002 mg/ml. SD50: sensitizing dose of peptides required to yield 50% maximal T-cell triggering of IFN-
c production. B) Spleen cells from the indicated group were evaluated for their proliferative capacity against the BF33 peptide, and the identification
of the specific T-cell subset was performed. For this, cells were dyed with CFSE and stimulated with BF33 peptide during 5 days and then staining
with surface antibodies was performed (CD3, CD4 and CD8). i- Representative dot plots. Numbers inside the graphs represent the average values for
duplicated samples. ii- Bars represent the average of duplicated samples plus SD. Background values obtained in cell-cultures stimulated with RPMIc,
were subtracted in each case. T test was applied, *p,0.05, * * p,0.005.
doi:10.1371/journal.pone.0037801.g006
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avidity of the cross-reactive T-cells. In a previous work from our
lab, no differences were found in T-cell avidity comparing EnvB
and EnvBF peptides (13BF vs 16B, located on the C1 region, aa 61
to 75) that differed in only two aa located at one end of the
peptides. In line with this result, no differences in the magnitude of
the responses against those peptides were found [44]. Limited
cross-reactivity against altered peptide ligands, with an aa
substitution in a central epitope position, was previously demon-
strated in a lymphocytic choriomeningitis virus (LCMV) model, in
which the authors also showed that these type of aa changes were
only able to mediate moderate anti-viral protection [58].
The highest avidity against the B84 peptide (representing a
cross-subtype response) found after IL-12 co-administration may
be explained by IL-12 properties described in earlier studies where
it is shown that this cytokine promotes an enhanced synapse
formation between APCs and T-cells, leading to the recognition of
weak peptides against which the T cells would be normally
unresponsive [59]. Moreover, another study also described that
the generation of high-avidity effector CTLs is IL-12 dependent
[60]. Regarding the use of other adjuvants and their effects on T-
cell avidity, it has been recently published that the use of three
TLR ligands (MALP2 (TLR2 ligand), poly(I:C) (TLR3) and CpG
(TLR9)) as adjuvants, augmented the quality of the Env specific T-
cell response amplifying their functional avidity [61].
In conclusion, this study shows that by including cytokines such
as IL-12 and/or GM-CSF expressed from DNA vectors during the
priming doses of DNA/MVA schemes, the cellular response
generated against the delivered antigen (NefBF) could be
improved. A summary of the results obtained along this study is
presented in Table 1. The use of IL-12 showed the best results
both generating significant increases in the magnitude of the
induced cellular immune response and also superior T-cell
properties in terms of breadth, cross-reactivity and quality (avidity
and pattern of cytokines secreted). These results are of relevance
contributing to the design of strategies aimed to induce responses
against HIV antigens with a superior breadth, avidity and cross-
reactivity against multiple viral subtypes.
Materials and Methods
1. Cell lines
Cell lines employed in the study were: BHK-21 (fibroblast cell-
line derived from baby hamster kidney, ATCC Cat No CCL-10)
and 293-T (epithelial cell line derived from human kidney cells,
ATCC Cat No CRL-1573). Cells were maintained at 37uCi na
5% CO2 atmosphere in Dulbecco’s Modified Eagle’s Medium
(Gibco BRL, USA) supplemented with 10% fetal bovine serum
(Natocor), 2 mM Lglutamine (Gibco BRL), 100 U/ml penicillin
(Gibco BRL) and 100 mg/ml streptomycin (Gibco BRL)
(DMEMc).
2. Viral stocks for immunization
MVA recombinant virus encoding NefBF protein was
previously developed in our lab [42]. MVAnefBF viral stock
employed for immunizations were grown in BHK-21 cells. MVA
stock was purified through 45% sucrose-cushion as elsewhere
indicated [62] and then titrated by immunostaining of fixed
BHK-21 infected cell-cultures with polyclonal serum reactive
against VV proteins.
Table 1. Results summary.
Prime: DNA 36NefBF plus - IL-12 GM-CSF IL-12+GM-CSF
Boost: MVAnefBF MVAnefBF MVAnefBF MVAnefBF
Magnitude IFN-c SFC/10
6 cells median [range] 169 [79–296] 457 [275–621] 289 [142–477] 296 [176–845]
Increase median respect to control
group [range]
- 2.38 [1.21–2.71] 1.73 [1–1.91] 1.53 [1.05–2.86]
Breadth S Frequency of NefBF structural
domains recognized
a
2 332
S Frequency of PTE structural
domains recognized
2 2.33 21
S Frequency of BF peptides recognized 2 2.32 2.32 2
S Frequency of B peptides recognized 1.08 1.5 1.5 0.66
Quality Pattern of cytokines
secreted
b
IFN ++++= ++++= +++22
TNF +++== + ==== ++===
IL-2 + ==== 22=== ++++=
Avidity SD50 BF33 (mg/ml) 0.0676 0.0995 ND ND
SD50 B84 (mg/ml) 1.246 0.4414 ND ND
Prolif-erative capacity %BF33-specific
CD4
+ cells
0.355 0.903 ND 0.940
%BF33-specific
CD8
+ cells
0.02 1.395 ND 1.855
SD50: sensitizing dose of peptide concentration required to induce half-maximum of the maximum number of specific IFN-c secreting cells.
ND: non determined.
aSum of the recognition frequencies (from 0 to1) of each of the five NefBF structural domains. For example: Control group: 1(N-t)+0 (Nt-C)+0(OCC)+1(L)+0(C-t)=2.
b+/2/=: significant increase/decrease/or no-changes in the level of cytokines produced against each of the 5 targeted peptides compared to control group.
With bold and italic letter it is indicated the best response found compare to control group.
doi:10.1371/journal.pone.0037801.t001
IL12 and GMCSF Improved HIV T-Cell Responses
PLoS ONE | www.plosone.org 13 May 2012 | Volume 7 | Issue 5 | e378013. DNA for immunization
The DNA plasmid expressing NefBF was described before [42].
The DNA plasmids carrying the sequence coding for IL-12
[30,39] and GM-CSF were kindly provided by Dr. Mariano
Esteban, National Centre of Biotechnology of the Autonomous
University of Madrid, Spain. In the case of GM-CSF vector, which
has not been described previously, an assay to quantify the amount
of cytokine released into the supernatant of transfected cells was
conducted. For this, 293-T cells were transfected with 10 mgo f
DNA-GM-CSF, using Lipofectamine (Invitrogen, USA), following
the manufacturer’s instructions. The amount of cytokine was
quantified in the supernatant by ELISA, 48 h post-transfection
(ELISA Kit, Peprotech, Mexico). Transfected cells produced
150 mg/ml of GM-CSF in average (versus 0.2 mg/ml of untrans-
fected cells) thus verifying the ability of the vector to express this
molecule (data not shown).
Plasmids were purified with Endo free Maxi-Prep purification
kits (NucleoBond Xtra Maxi Plus EF, Macherey-Nalgen, Ger-
many) using pyrogen-free material and eluted in 200 ml/column
pyrogen-free TE buffer and then diluted for injection in sterile
PBS.
4. Mice immunization protocols, sample collection and
processing
Six- to eight-week-old female specific-pathogen-free (SPF)
BALB/c mice (H-2d) were purchased from the Laboratories of
the School of Veterinary Sciences, University of La Plata, Buenos
Aires, and then housed in our animal facilities. All experiments
were done in compliance with legal and institutional guidelines
[63]. The protocol was approved by the Committee of Care and
Use of Laboratory Animals from the School of Medicine,
University of Buenos Aires (Permit Number: 508/2009).
DNA doses (50 mg each one) were applied in 100 ml of sterile
PBS by the intramuscular (i.m.) route, whereas immunizations
with viral vectors (MVA, 10
7 PFU) were given intraperitoneally
(i.p.) in 200 ml PBS. In the immunization schemes applied, doses
were always spaced by intervals of 14 days. Mice were sacrificed
nine days after the last immunization and spleens were recovered
under sterile conditions. Splenocytes were isolated by standard
procedures. The number of animals of each of the experimental
groups of the study was of 4. Then the T-cell assays were
performed with pooled cells from the 4 mice of each group.
5. Peptides
Overlapping synthetic peptides (13–15-mers, overlapping by 11
amino acids (aa)) were designed based on the Nef protein from
CRF12_BF reference strain ARMA185 (GenBank accession
number AY037279), the same sequence employed for the
construction of the DNA and MVA, and custom ordered from
JPT Peptide Technologies (Germany) [20,42]. They were used
either as i) a single pool, representing the full protein; ii) as five
pools, representing each protein domain: N-terminal domain (N-t,
comprising since the first amino acid (aa) to 83), N-terminal Core
(Nt-C, 84 to 115), Oligomerization domain and Central Core
(OCC, 116–159), the Loop of the protein (L, 160–187) and the C-
terminal domain (C-t, 188–205); iii) as 12 pools of 6 peptides
generating a NefBF matrix where each peptide was represented in
two different peptide pools, allowing for the identification of the
respective peptide by responses in the two corresponding pools as
previously described by Turk et al [20]; iv) or as single peptides.
Overlapping synthetic peptides of NefB consensus protein and
PTE peptides were obtained from the NIH AIDS Reagent
Program. The NefB peptides were used as i) a single pool,
representing the full protein, ii) as 14 pools of 7 peptides forming a
B matrix where each peptide was represented in two different
peptide pools, allowing for the identification of the respective
peptide by responses in the two corresponding pools as previously
described [20], iii) or as single peptides.
The PTE peptide set represent the most frequent potential T-
cell epitopes (PTE) embedded in the sequences of circulating HIV-
1 strains of HIV-1 worldwide. The peptides are 15 aa in length.
The global PTE peptides cover all PTEs with a frequency equal to
or greater than 15% in any one of the subtypes A, B, C and non-
ABC. Here, the PTE peptides were pooled in three pools
representing the N-terminal (N-t, aa 1 to 83), Central (Cent, 84
to 159) and C-terminal (C-t, 160 to 205) portion of the protein.
In all the cases, lyophilized peptides were dissolved in dimethyl
sulfoxide (DMSO) and stored at 220uC.
All the pools were used as stimulus in the ELISPOT assay, to
stimulate the cells for subsequent ELISA assays and for flow
cytometry assay. In all the cases the final peptide concentration
was of 2 mg/ml.
6. Murine IFN-c ELISPOT assays
ELISPOT assays were performed with freshly isolated spleno-
cytes cultured in RPMIc (RPMI-1640 medium (Gibco BRL,)
supplemented with 10% fetal bovine serum (Natocor), 2 mM
Lglutamine (Gibco BRL), 100 U/ml penicillin (Gibco BRL),
100 mg/ml streptomycin (Gibco BRL), and 10 mM HEPES
(Gibco BRL) and b-Mercaptoetanol….) as described previously
[42]. Briefly, 0.125610
6 to 10
6 cells were plated on duplicate or
triplicate wells in 96-well ELISPOT plates (MultiScreen IP plates,
Millipore, USA) previously coated with anti-mouse IFN-c Ab (BD
ELISPOT mouse IFN-c ELISPOT pair). Peptide pools or single
peptides were added at a final concentration of 2 mg/ml. Negative
controls consisted of peptide-free medium plus 0.5% DMSO.
Concanavalin A (ConA, Sigma-Aldrich, Germany) at 1 mg/ml was
included as positive control. Plates were incubated for 36 h in a
37uC incubator with a 5% CO2 atmosphere, later washed
extensively with PBS plus 0.05% Tween 20 (PBS-T) and incubated
during 16–18 h at 4uC with the detecting Ab solution (BD
ELISPOT mouse IFN-c ELISPOT pair). Thereafter, plates were
washed and incubated during 1 h with peroxidase-labeled
streptavidin–avidin (BD PharMingen, USA). After 1 h, wells were
washed and spots were developed by adding a 1 mg/ml solution of
the substrate 3.3-diaminobenzidine tetrahydrochloride (Sigma-
Aldrich) containing 0.015% hydrogen peroxide. Plates were
scanned on an ImmunoSpot reader (Cellular Technology Ltd.).
Specific spots were counted and the spot mean sizes were
calculated using the ImmunoSpot software.
Functional avidity referred to as the activation threshold in
response to defined concentrations of exogenous peptide was
performed following the protocols previously described [46].
Briefly, limiting peptide dilutions (from 20 to 0.002 mg/ml) were
performed and then the sensitizing dose of peptide concentration
required to induce a half-maximum IFN-c secreting cells (SD50)i n
ex vivo assays was determined with a sigmoid dose-response curve
(GraphPad software).
7. T cell-specific cytokine production
Splenocytes were resuspended in RPMIc and cultured in
triplicate wells (10
6 cells/well) into 96-well microtiter flat-bottom
plates and stimulated with single NefBF or NefB peptides at a final
concentration of 2 mg/ml, Con A (1 mg/ml; Sigma–Aldrich), or
medium alone with 0.5% DMSO. After 72 h of incubation at
37uCi n5 %C O 2, culture supernatants were harvested and stored
at 280uC until analyzed by ELISA for IFN-c TNF or IL-2 (BD
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were considered positive when values obtained were higher than
RPMI+2xSD.
8. Proliferation assay
Proliferation assay was performed using cryopreserved spleno-
cytes. After obtaining splenocytes, remaining cells were cryopre-
served in FBS plus 10% DMSO and stored in liquid N2 until their
use. On day 1, cryopreserved splenocytes were thawed and rested
during 6–8 hr in RPMIc, at 37uC in a 5% CO2 atmosphere. After
resting, cell viability was checked by trypan blue exclusion.
To evaluate the proliferation of BF33-specific T-cells, spleno-
cytes from mice were labeled with carboxyfluorescein succinimidyl
ester (CFSE) [55]. Briefly, splenocytes were resuspended (10
6 cells/
ml) in PBS plus 1% FBS and labeled with 1.25 mM of CFSE
(Molecular Probes, USA) at 37uC for 8 minutes. The reaction was
quenched with FBS and cells were washed with RPMIc. Then,
cells were resuspended in RPMIc at a density of 5610
6/ml. Cells
were cultured in M12 plates for 5 days at 37uC and 5% CO2
atmosphere with medium only or 2 mg/ml of BF33 peptide.
Positive controls were stimulated with ConA. At the fifth day,
splenocytes were harvested, counted and washed with RPMIc.
Then, cells were stained for 20 minutes at 4uC with anti-mouse
CD3 allophycocyanin (APC), peridinin chlorophyll protein
(PerCP)-conjugated anti-mouse CD4 or CD8 monoclonal anti-
bodies (BD Biosciences) plus viability dye near-IR-fluorescent
reactive (LIVE/DEAD, Invitrogen). Cells were then washed and
acquired in a BD FACSCanto flow cytometer. Data acquisition
and analysis was performed using the BD FACSDiva software.
Instrument setting and fluorescence compensation were performed
for each day of testing using unstained and single-stained samples.
Initial gating was performed on small lymphocytes in a forward
scatter versus side scatter (SSC) plot. At least 100.000 events were
acquired in the lymphocyte gate. The viable cells were gated on a
LIVE/DEAD histogram. The percentage of CD3
+CD4
+ and
CD3
+CD8
+ proliferating (CFSE low) cells was determined after
gating cells in a CD3 versus CD4 or CD8 plot.
9. Bioinformatic analysis
The MHC binding affinity of peptides was predicted using the
web based immunology tools SYFPEITHI Epitope Prediction
(Class I: Ld and Kd; Class II: Ad and Ed) and PREDEP (Class I:
Dd) prediction softwares.
10. Data analysis
In ELISPOT and ELISA assays, positivity threshold in peptide-
stimulated wells was calculated as at least 2 times the average plus
one SD value of negative control wells for each group.
Mann-Whitney test was used to compare inter-group responses
in figure 1 (n.3). Student’s t-test was used to compare frequencies
among the groups. For all tests, a value of p,0.05 was considered
statistically significant.
Supporting Information
Figure S1 IL-12 and GM-CSF enhanced the NefBF IL-2
immune response. Nine days after the boost dose, cellular
immune response against NefBF was evaluated in the spleen,
quantifying the number of specific IL-2 secreting cells by
ELISPOT. Background values found in negative control wells
(RPMI plus DMSO) were subtracted and ranged from 5 to 30
spots/well. Bars represent the average of duplicated samples plus
SD. Data is from a representative experiment out of two.
Significant differences (T test) between control vs the other three
groups are indicated with * p,0.05 and **p,0.005.
(TIF)
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